A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
Status:
Completed
Trial end date:
2019-09-04
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab
versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic
disease-modifying anti-rheumatic drugs (DMARD) naive.